Could a transplant drug shrink Children's birthmarks?

NCT ID NCT02509468

Completed Disease control Sponsor: University Hospital, Tours Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested the drug sirolimus (rapamycin) in 63 children aged 6 to 18 with large, complicated slow-flow vascular malformations (abnormal blood or lymph vessels). Each child had an observation period followed by 4 to 8 months of sirolimus treatment. The main goal was to see if the malformation shrank on MRI scans. The trial is completed, and results may help decide if sirolimus is a useful treatment for these rare conditions.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: sirolimus (also known as rapamycin)
What this could lead to: If it works, this could point toward a drug treatment to shrink or control problematic vascular malformations in children, reducing pain and complications.
What could go wrong: This is a small, early-phase trial with only 63 children and no placebo group. The results may not apply to all types of malformations, and sirolimus can have side effects like mouth sores and infections.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MICROCYSTIC LYMPHATIC MALFORMATION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

microcystic lymphatic malformation mixed cystic lymphatic malformation vascular malformation venous hemangioma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

VASCULAR MALFORMATION

Contacts and locations

Locations

Consultations externes de Dermatologie, Hôpital Clocheville, CHU Tours

Tours, 37000, France
Explorations Médecine Vasculaire Hôpital A. Michallon, CHU de Grenoble

Grenoble, 38700, France
Service de Dermatologie, Hôpital Hôtel-Dieu, CHU Nantes

Nantes, 44000, France
Service de Dermatologie, Hôpital Pontchaillou, CHU RENNES

Rennes, 35000, France
Service de Dermatologie, Hôpital St Eloi, CHU Montpellier

Montpellier, 34000, France
Service de Dermatologie, vénéréologie et cancérologie cutanée, Hôpital La Timone APHM

Marseille, 13000, France
Service de dermatologie, APHP Necker

Paris, 75743, France
Service de dermatologie, CHU Angers

Angers, 49933, France
Service de dermatologie, CHU Nice

Nice, 06202, France
Service de dermatologie, Hôpital Larrey, CHU Toulouse

Toulouse, 31059, France
Service de dermatologie, Hôpital du Bocage, CHU Dijon

Dijon, 21079, France
Service de radiologie Hôpital Femme-Mère-Enfant, Hospices Civils de Lyon

Lyon, 69000, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.